Growth Metrics

Omeros (OMER) Liabilities and Shareholders Equity (2010 - 2026)

Omeros recorded quarterly Liabilities and Shareholders Equity of $286.2 million in Q1 2026, down 12.12% quarter-over-quarter from $325.6 million in Q4 2025, and up 21.69% year-over-year from $235.2 million in Q1 2025.

Omeros' Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $286.2 million for Q1 2026.

  • In Q1 2026, Liabilities and Shareholders Equity rose 21.69% year-over-year to $286.2 million; the TTM figure through Mar 2026 stood at $998.1 million (down 15.55% YoY), while the FY2025 annual figure was $325.6 million, up 17.52% from the prior year.
  • Liabilities and Shareholders Equity came in at $286.2 million for Q1 2026 at Omeros, down from $325.6 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $591.0 million in Q4 2022 to a low of $185.7 million in Q3 2025.
  • A 5-year average of $372.9 million and a median of $356.3 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
  • Across the five-year window, Liabilities and Shareholders Equity surged 270.7% in 2022 and plunged 46.25% in 2025, its largest moves.
  • Omeros' Liabilities and Shareholders Equity stood at $591.0 million in 2022, then sank by 35.99% to $378.3 million in 2023, then declined by 26.75% to $277.1 million in 2024, then climbed by 17.52% to $325.6 million in 2025, then decreased by 12.12% to $286.2 million in 2026.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $286.2 million, $325.6 million, and $185.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 14.93 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - 37.37 Mn
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 1.73 Bn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - 78.88 Mn
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 33.89 Mn
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 26.48 Bn
7 Evaxion A 62.56 Bn 62.54 Bn - 23.64 Mn
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 40.87 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 5.13 Bn
10 Omeros 772.03 Mn 636.71 Mn 9.31 Mn 286.17 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 286.17 Mn
Dec 31, 2025 325.63 Mn
Sep 30, 2025 185.71 Mn
Jun 30, 2025 200.57 Mn
Mar 31, 2025 235.16 Mn
Dec 31, 2024 277.08 Mn
Sep 30, 2024 313.34 Mn
Jun 30, 2024 356.31 Mn
Mar 31, 2024 437.49 Mn
Dec 31, 2023 378.27 Mn
Sep 30, 2023 493.07 Mn
Jun 30, 2023 527.42 Mn
Mar 31, 2023 560.13 Mn
Dec 31, 2022 590.97 Mn
Sep 30, 2022 457.55 Mn
Jun 30, 2022 345.64 Mn
Mar 31, 2022 369.26 Mn
Dec 31, 2021 419.27 Mn
Sep 30, 2021 123.43 Mn
Jun 30, 2021 145.39 Mn
Mar 31, 2021 161.44 Mn
Dec 31, 2020 181.04 Mn
Sep 30, 2020 227.08 Mn
Jun 30, 2020 70.69 Mn
Mar 31, 2020 118.21 Mn
Dec 31, 2019 136.97 Mn
Sep 30, 2019 91.26 Mn
Jun 30, 2019 89.76 Mn
Mar 31, 2019 101.25 Mn
Dec 31, 2018 95.94 Mn
Sep 30, 2018 75.61 Mn
Jun 30, 2018 106.35 Mn
Mar 31, 2018 89.04 Mn
Dec 31, 2017 116.33 Mn
Sep 30, 2017 125.52 Mn
Jun 30, 2017 60.35 Mn
Mar 31, 2017 58.40 Mn
Dec 31, 2016 67.28 Mn
Sep 30, 2016 72.76 Mn
Jun 30, 2016 46.11 Mn
Mar 31, 2016 35.97 Mn
Dec 31, 2015 49.00 Mn
Sep 30, 2015 41.42 Mn
Jun 30, 2015 58.64 Mn
Mar 31, 2015 74.91 Mn
Dec 31, 2014 10.83 Mn
Sep 30, 2014 25.29 Mn
Jun 30, 2014 40.99 Mn
Mar 31, 2014 56.07 Mn
Dec 31, 2013 16.54 Mn
Sep 30, 2013 12.01 Mn
Jun 30, 2013 23.06 Mn
Mar 31, 2013 17.69 Mn
Dec 31, 2012 26.58 Mn
Sep 30, 2012 32.76 Mn
Jun 30, 2012 10.07 Mn
Mar 31, 2012 21.09 Mn
Dec 31, 2011 26.98 Mn
Sep 30, 2011 34.98 Mn
Jun 30, 2011 40.95 Mn
Dec 31, 2010 45.70 Mn